Overview

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2027-03-31

Target enrollment:

Participant gender:

Summary

To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.

Phase:

Early Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Acerta Pharma, LLC
Kite, A Gilead Company

Treatments:

Acalabrutinib
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine